Pasithea Therapeutics Launches In-Home Intravenous Ketamine Therapy in Major U.S. Cities, Expanding its International Footprint
November 17 2021 - 8:00AM
Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the
“Company”), a novel biotechnology company focused on the research
and discovery of new and effective treatments for psychiatric and
neurological disorders, today announced that its wholly owned
subsidiary, Pasithea Clinics, commenced clinical operations,
offering in-home intravenous (“IV”) ketamine therapy to patients
suffering from treatment-resistant mental health issues. Initially,
the treatment will be offered in New York City, Los Angeles, San
Diego, and San Francisco and will expand nationwide in the coming
months.
“The need for more effective treatment options
for patients with mental health disorders has never been greater.
Ketamine, when used at sub-anesthetic doses, has been shown to be
highly effective in treating some psychiatric disorders. Still, we
need to broaden access to this treatment to a larger patient
population in a safe and convenient way. Through our mobile
clinics, patients benefit from receiving the ketamine therapy in
the privacy and comfort of their own homes. With patient safety as
our top priority, all ketamine treatments will be delivered by
board-certified medical professionals. This launch is an important
stepping stone in expanding our international footprint in this
space,” stated Dr. Tiago Reis Marques, CEO of Pasithea
Therapeutics.
Patients with mental health disorders often
struggle to complete day-to-day activities, and even small tasks
can take extra effort. In disorders such as depression and
post-traumatic stress disorder, symptoms such as fatigue, social
isolation, lack of motivation, and high levels of anxiety are
frequent. The effort to go to a physical clinic can be
overwhelming. By providing this treatment at the patient’s home,
Pasithea aims to broaden access to this important therapy.
“We are pleased to commence our U.S. rollout in
major cities in New York and California, with plans to scale our
business in other cities over the coming months. Although ketamine
is a very safe drug to administer, there are still some risks.
Patient safety is of paramount importance, and we are providing a
network of highly trained medical professionals to administer this
treatment in the comfort of the patient´s home. Our medical team
ensures that our patients receive state-of-the-art support
throughout their treatment experience. We believe we can become the
best-in-class and largest provider of IV ketamine treatments in the
United States. We will use our at-home model to expand our reach in
the U.S. in a fast and accessible way,” said Dr. Adam Nadelson,
Managing Director of Pasithea Clinics in the United States.
Ketamine is a U.S. Food and Drug Administration
(“FDA”) approved drug introduced to the medical community as an
anesthetic more than 50 years ago. It has recently been repurposed
for the treatment of psychiatric disorders using significantly
lower doses than in anesthesia and is now gaining ground as a
promising treatment for mental health disorders. In certain
psychiatric conditions, such as treatment-resistant depression
(“TRD”) and post-traumatic stress disorder (“PTSD”), it has shown
remarkable efficacy and a rapid and sustained effect, and up to 70%
of those who receive this treatment can eventually show a clinical
response. While the number of treatments suggested is done on a
case-by-case basis, a typical treatment plan consists of up to six
infusions in the interval of two to three weeks.
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corporation is a U.S.
biotechnology company focused on the research and discovery of new
and effective treatments for psychiatric and neurological
disorders. With an experienced team of experts in the fields of
neuroscience and psychopharmacology, Pasithea is developing new
molecular entities for the treatment of psychiatric and
neurological disorders. Pasithea is also focused on addressing the
needs of patients currently suffering with mental illness by
providing access to IV ketamine infusions both in clinics and
in-home settings.
Forward Looking Statements
This press release contains statements that
constitute “forward-looking statements.” Forward-looking statements
are subject to numerous conditions, many of which are beyond the
control of the Company. While the Company believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to the Company on the date of this
release. These forward-looking statements are based upon current
estimates and assumptions and are subject to various risks and
uncertainties, including, without limitation, those set forth in
the Company’s filings with the SEC. Thus, actual results could be
materially different. The Company undertakes no obligation to
update these statements whether as a result of new information,
future events or otherwise, after the date of this release, except
as required by law.
Pasithea Therapeutics Corp. Company ContactDr.
Tiago Reis MarquesChief Executive OfficerE: tiago@pasithea.com
Pasithea Therapeutics Corp. Investor
RelationsLisa M. WilsonIn-Site Communications, Inc.T:
212-452-2793E: lwilson@insitecony.com
Pasithea Therapeutics (NASDAQ:KTTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pasithea Therapeutics (NASDAQ:KTTA)
Historical Stock Chart
From Apr 2023 to Apr 2024